Egalet Announces Investor Day

--Company to provide update on commercial launch of SPRIX® Nasal Spray and OXAYDO™ and pipeline products, including abuse-deterrent, extended-release morphine, Egalet-001--

Sep 15, 2015, 06:00 ET from Egalet Corporation

WAYNE, Pa., Sept. 15, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announces plans to host its first investor day on Tuesday, September 29, 2015 to provide an update on the marketed and development products to the investment community. Company presentations will be made by Bob Radie, president and chief executive officer, Deanne Melloy, chief commercial officer, Jeffrey Dayno, MD, chief medical officer, Mark Strobeck, PhD, chief business officer and head of strategic planning, and Stan Musial, chief financial officer. In addition, Lynn Webster, MD, vice president, scientific affairs, PRA International, will discuss the problem of pain and the role for abuse-deterrent formulations. The event will take place in New York City with registration beginning at 8:15 AM ET and presentations beginning at 9:00 AM ET.

The presentations will be webcast live and can be viewed via the webcast available at The program should conclude by 12:00 PM ET.

About Egalet Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative pain treatments. The Company has two approved products: OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using Egalet's proprietary Guardian™ Technology, the Company is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Full additional information on Egalet, please visit

Safe Harbor Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet's clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet's ability to obtain regulatory approval of Egalet's product candidates; Egalet's ability to maintain the intellectual property position of Egalet's products and product candidates; Egalet's ability to identify and reliance upon qualified third parties to manufacture its products; Egalet's ability to service its debt obligations; Egalet's ability to find and hire qualified sales professionals; the receptivity in the marketplace and among physicians to Egalet's products; the success of products which compete with Egalet's that are or become available; general market conditions; and other risk factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Investor and Media Contact: E. Blair Clark-Schoeb Senior Vice President, Communications Email: Tel: 917-432-9275

Logo -


SOURCE Egalet Corporation